Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision tag updated from v3.5.3 to v3.5.4 on the page, indicating a minor update to the study record.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s displayed revision/version identifier was updated from v3.5.2 to v3.5.3, indicating a site or interface software update rather than a change to the clinical trial information.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page now displays Revision: v3.5.0 and no longer shows Revision: v3.4.3.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check94 days agoChange DetectedThe page update shows a revision from v3.4.1 to v3.4.2. No substantive changes to study content or key details such as eligibility criteria or outcomes are evident.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.